Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IRReportar como inadecuado

Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Malignant clonal cells purification can greatly benefit basic and clinical studies in myelodysplastic syndrome MDS. In this study, we investigated the potential of using type 1 insulin-like growth factor receptor IGF-IR as a marker for purification of malignant bone marrow clonal cells from patients with MDS. The average percentage of IGF-IR expression in CD34+ bone marrow cells among 15 normal controls was 4.5%, 70% of which also express the erythroid lineage marker CD235a. This indicates that IGF-IR mainly express in erythropoiesis. The expression of IGF-IR in CD34+ cells of 55 MDS patients was significantly higher than that of cells from the normal controls 54.0 vs. 4.5%. Based on the pattern of IGF-IR expression in MDS patients and normal controls, sorting of IGF-IR-positive and removal of CD235a-positive erythroid lineage cells with combination of FISH detection were performed on MDS samples with chromosomal abnormalities. The percentage of malignant clonal cells significantly increased after sorting. The enrichment effect was more significant in clonal cells with a previous percentage lower than 50%. This enrichment effect was present in samples from patients with +8, 5q-5, 20q-20 or 7q-7 chromosomal abnormalities. These data suggest that IGF-IR can be used as a marker for MDS bone marrow clonal cells and using flow cytometry for positive IGF-IR sorting may effectively purify MDS clonal cells.

Autor: Qi He, Chun-Kang Chang , Feng Xu, Qing-Xia Zhang, Wen-Hui Shi, Xiao Li

Fuente: http://plos.srce.hr/


Documentos relacionados